Moleac
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
92 Rue De La Victoire, Paris, Ile-de-Fra...Phone Number
+33 148784261Website
www.moleac.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Moleac
Moleac is a biopharmaceutical company dedicated in finding, developing and commercializing worldwide new medicines for the unmet medical needs of patients suffering of central nervous system (CNS) diseases and injuries, such as stroke, dementia and traumatic brain injuries. To address therapeutic gaps, Moleac has pioneered a new drug development approach, looking at sources of innovation from Natural Medicines, hence shortening considerably drug development cycle time and investment to bring medicine to sufferers' unaddressed needs. Moleac's neurorestorative natural formulation NeuroAiD reaches patients in more than 30 countries where it is regulated.Explore more
Moleac Org Chart
Get the full picture
Sign in to uncover key details.
KL
Accounts Receivable Executive
EL
Accounts Payable Executive
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Moleac your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Moleac launches new products
Check if Moleac has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Moleac has new funding data
Check out if Moleac is spiking on competitors!
Moleac, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Moleac recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Moleac had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Moleac
Recommended Actions
Find VP level buyers at Moleac
Find more new buyers
Company Profile Activity
Activity Insights
Moleac is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Moleac is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Moleac.
Moleac Tech Stack
A closer look at the technologies used by Moleac
Moleac News & Media
Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia
SINGAPORE, Oct. 21, 2024 /PRNewswire/ -- Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as PT Ferron Par Pharmaceuticals will become our exclusive partner in Indonesia effective Jan 1st 2025. We are immensely grateful for the fruitful 12-year...Moleac launches CognivAiD™, a novel targeted product for vascular dementia
CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia. CognivAiD demonstrated significant and clinically meaningful disease-modifying benefits in clinical trials based on VaDAS-Cog and ADCS-CGIC scales, with a favourable safety profile.CognivAiD has a unique ‘multimodal mechanism of action’, reinforcing Moleac’s dedication to developing scientifically proven innovative formulations for patients with neurological conditions. SINGAPORE, Jan. 16, 2023NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries
SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). NeuroAiD was safe as add-on treatment in patients with severe SCI. One third of patients improved on ASIA...NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 12, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Moleac
Sign Up For FreeTo access detailed company insights
Moleac is a biopharmaceutical company dedicated in finding, developing and commercializing worldwide new medicines for the unmet medical needs of patients suffering of central nervous system (CNS) diseases and injuries, such as stroke, dementia and traumatic brain injuries. To address therapeutic gaps, Moleac has pioneered a new drug development ap... Read More
